Research Article
Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
Table 2
C.E.R.A. administration (safety population,
).
| Reason for initiation of C.E.R.A., (%)a | | New and innovative application scheme | 173 (62.2) | No previous ESA therapy | 86 (30.9) | Therapeutic failure of previously used ESA | 16 (5.8) | Adverse effects of previously used ESA | 2 (0.7) | Other | 5 (1.8) | Route of application, (%) | | Subcutaneous | 260 (93.2) | Subcutaneous and intravenous | 3 (1.1) | Unknown | 16 (5.7) | Application by, (%) | | Patient | 180 (64.5) | Patient or nurse | 1 (0.4) | Physician | 28 (10.0) | Physician or patient | 69 (24.7) | Physician or patient or nurse | 1 (0.4) | C.E.R.A. dose per application, µg | | Initial dose | | Mean (SD) | 92.2 (56.0) | Median (range) | 75.0 (30–360) | Final dose, mean (SD) | | Mean (SD) | 98.8 (59.5) | Median (range) | 75.0 (30–360) | Throughout study | | Mean (SD) | 95.1 (53.2) | Median (range) | 76.9 (30–360) | Time between C.E.R.A. applications, days | | Mean (SD) | 34.0 (11.9) | Median (range) | 31.2 (13–91) | C.E.R.A. dose changes, (%) | | No dose change | 119 (42.7) | Any dose change | 160 (57.3) | Any dose decrease |
117 (41.9) | Any dose increase | 132 (47.3) |
|
|
C.E.R.A.: continuous erythropoietin receptor activator; SD: standard deviation.
aMore than one reason could be selected from a preprinted list.
|